Lilly’s Obesity Drug Shortage Resolved, Novo’s Continues Amid Industry Efforts to Boost Manufacturing

Lilly's Shortage Resolved:
The FDA has confirmed that the shortage of Eli Lilly's obesity drugs, Mounjaro and Zepbound, has been resolved.

Novo's Shortage Continues:
Novo Nordisk's obesity drug, Wegovy, particularly the 0.25mg starter dose, remains in short supply.

Impact on Compounded Drugs:
The end of Lilly's shortage may limit the availability of compounded versions of these drugs, which were popular during the shortage due to lower costs and easier access.

Industry Efforts:
Pharmaceutical companies are investing heavily in manufacturing to meet the high demand for GLP-1 drugs, with Lilly's supply stability seen as a competitive advantage.

Future Market Dynamics:
The GLP-1 market is expected to see significant growth, with new entrants and next-generation drugs potentially challenging Lilly and Novo's dominance.